MCID: CNC001
MIFTS: 37

Cancerophobia

Categories: Cancer diseases, Mental diseases

Aliases & Classifications for Cancerophobia

MalaCards integrated aliases for Cancerophobia:

Name: Cancerophobia 12 15 17 74
Fear of Getting Cancer 12
Cancer Phobia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:602
NCIt 51 C35492
SNOMED-CT 69 34563004
UMLS 74 C0233705

Summaries for Cancerophobia

MalaCards based summary : Cancerophobia, also known as fear of getting cancer, is related to breast medullary carcinoma and papillary serous adenocarcinoma. An important gene associated with Cancerophobia is MCIDAS (Multiciliate Differentiation And DNA Synthesis Associated Cell Cycle Protein), and among its related pathways/superpathways are Homologous DNA Pairing and Strand Exchange and Cell cycle Role of SCF complex in cell cycle regulation. The drugs Norepinephrine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and bone, and related phenotypes are Decreased homologous recombination repair frequency and Decreased homologous recombination repair frequency

Wikipedia : 77 Cancer phobia, also known as carcinophobia, is an anxiety disorder characterized by the chronic fear of... more...

Related Diseases for Cancerophobia

Diseases related to Cancerophobia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 46)
# Related Disease Score Top Affiliating Genes
1 breast medullary carcinoma 10.0 BRCA1 PGR
2 papillary serous adenocarcinoma 10.0 BRCA1 PGR
3 uterine corpus cancer 10.0 BRCA1 PGR
4 in situ carcinoma 9.9 BRCA1 PGR
5 estrogen-receptor negative breast cancer 9.9 BRCA1 PGR
6 hereditary site-specific ovarian cancer syndrome 9.8 BRCA1 BRCA2
7 tuberculous salpingitis 9.8 BRCA1 BRCA2
8 breast reconstruction 9.8 BRCA1 BRCA2
9 breast ductal carcinoma 9.8 BRCA1 PGR
10 breast-ovarian cancer, familial 1 9.8 BRCA1 BRCA2
11 fallopian tube adenocarcinoma 9.8 BRCA1 BRCA2
12 premature menopause 9.8 BRCA1 BRCA2
13 peritoneum cancer 9.8 BRCA1 BRCA2
14 fallopian tube disease 9.8 BRCA1 BRCA2
15 lynch syndrome 9.8 BRCA1 BRCA2
16 lynch syndrome i 9.8 BRCA1 BRCA2
17 mutagen sensitivity 9.8 BRCA1 BRCA2
18 fanconi anemia, complementation group q 9.8 BRCA1 BRCA2
19 ovarian cancer 1 9.7 BRCA1 BRCA2
20 hereditary breast ovarian cancer syndrome 9.7 BRCA1 BRCA2
21 gonadal disease 9.7 BRCA1 BRCA2
22 li-fraumeni syndrome 9.7 BRCA1 BRCA2
23 endocrine gland cancer 9.6 BRCA1 BRCA2
24 synchronous bilateral breast carcinoma 9.6 BRCA1 BRCA2 PGR
25 glycogen-rich clear cell breast carcinoma 9.6 BRCA1 BRCA2 PGR
26 bilateral breast cancer 9.6 BRCA1 BRCA2 PGR
27 primary peritoneal carcinoma 9.6 BRCA1 BRCA2 PGR
28 pre-malignant neoplasm 9.6 BRCA1 BRCA2 PGR
29 fallopian tube carcinoma 9.6 BRCA1 BRCA2 PGR
30 dysgerminoma of ovary 9.6 BRCA1 BRCA2 PGR
31 breast carcinoma in situ 9.6 BRCA1 BRCA2 PGR
32 pancreas adenocarcinoma 9.6 BRCA1 BRCA2
33 malignant ovarian surface epithelial-stromal neoplasm 9.6 BRCA1 BRCA2 PGR
34 ovary epithelial cancer 9.6 BRCA1 BRCA2 PGR
35 female breast cancer 9.5 BRCA1 BRCA2 PGR
36 ovarian cancer 9.5 BRCA1 BRCA2 PGR
37 sporadic breast cancer 9.5 BRCA1 BRCA2 PGR
38 ductal carcinoma in situ 9.5 BRCA1 BRCA2 PGR
39 female reproductive system disease 9.5 BRCA1 BRCA2 PGR
40 reproductive system disease 9.5 BRCA1 BRCA2 PGR
41 ovarian disease 9.5 BRCA1 BRCA2 PGR
42 breast disease 9.5 BRCA1 BRCA2 PGR
43 adamantinoma of long bones 9.5 BRCA1 BRCA2 PGR
44 fanconi anemia, complementation group a 9.4 BRCA1 BRCA2
45 endometrial cancer 9.4 BRCA1 BRCA2 PGR
46 nosophobia 9.3 BRCA1 BRCA2 MCIDAS PGR

Graphical network of the top 20 diseases related to Cancerophobia:



Diseases related to Cancerophobia

Symptoms & Phenotypes for Cancerophobia

GenomeRNAi Phenotypes related to Cancerophobia according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 10.4 BRCA1
2 Decreased homologous recombination repair frequency GR00151-A-2 10.4 BRCA1
3 Decreased homologous recombination repair frequency GR00236-A-1 10.4 BRCA1 BRCA2 PGR
4 Decreased homologous recombination repair frequency GR00236-A-2 10.4 BRCA1 BRCA2 PGR
5 Decreased homologous recombination repair frequency GR00236-A-3 10.4 BRCA1 BRCA2
6 Decreased viability after ionizing radiation GR00232-A-2 9.16 BRCA1 BRCA2
7 Decreased viability with cisplatin GR00101-A-4 8.96 BRCA1 BRCA2
8 Synthetic lethal with cisplatin GR00101-A-1 8.62 BRCA1 BRCA2

MGI Mouse Phenotypes related to Cancerophobia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 limbs/digits/tail MP:0005371 9.13 BRCA1 BRCA2 PGR
2 neoplasm MP:0002006 8.8 BRCA1 BRCA2 PGR

Drugs & Therapeutics for Cancerophobia

Drugs for Cancerophobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norepinephrine Approved Phase 3 51-41-2 439260
2
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
3
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
4
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
5
Tamoxifen Approved Phase 3 10540-29-1 2733526
6
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
7
Sodium Citrate Approved, Investigational Phase 3 68-04-2
8
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
9
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
10
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
11 Dopamine Agents Phase 3
12 Duloxetine Hydrochloride Phase 3
13 Antidepressive Agents Phase 3
14 Neurotransmitter Uptake Inhibitors Phase 3
15 Peripheral Nervous System Agents Phase 3
16 Aromatase Inhibitors Phase 3
17 Hormones Phase 3
18 Psychotropic Drugs Phase 3
19 Neurotransmitter Agents Phase 3
20 Analgesics Phase 3
21 Estrogens Phase 3
22 Serotonin and Noradrenaline Reuptake Inhibitors Phase 3
23 Estrogen Receptor Modulators Phase 3
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
25 Calcium, Dietary Phase 3
26 Anticoagulants Phase 3
27 Antineoplastic Agents, Hormonal Phase 3
28 Hormone Antagonists Phase 3
29 Selective Estrogen Receptor Modulators Phase 3
30 Citrate Phase 3
31 Chelating Agents Phase 3
32 Steroid Synthesis Inhibitors Phase 3
33 Estrogen Antagonists Phase 3
34 Estrogen Receptor Antagonists Phase 3
35 Bone Density Conservation Agents Phase 3
36
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
37
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
38
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 6857599 5310940 9887054 43805
39
Fluorouracil Approved Phase 2 51-21-8 3385
40
Pancrelipase Approved, Investigational Phase 2 53608-75-6
41
Gemcitabine Approved Phase 2 95058-81-4 60750
42
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
43
Camptothecin Experimental Phase 2 7689-03-4
44 Antiviral Agents Phase 2
45 Antimetabolites Phase 2
46 Anti-Infective Agents Phase 2
47 Immunosuppressive Agents Phase 2
48 pancreatin Phase 2
49 topoisomerase I inhibitors Phase 2
50 Albumin-Bound Paclitaxel Phase 2

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Completed NCT01598298 Phase 3 duloxetine hydrochloride
2 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
3 Brief CBT for Anxiety and Advanced Cancer Completed NCT00706290 Phase 2
4 Impact of a Group Intervention on Breast Cancer Patient's Adjustment and Emotion Regulation at the End of Treatment Completed NCT01797354 Phase 2
5 S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Recruiting NCT02562716 Phase 2 Fluorouracil;Gemcitabine Hydrochloride;Irinotecan Hydrochloride;Oxaliplatin;Paclitaxel Albumin-Stabilized Nanoparticle Formulation
6 Fear of Recurrence Pilot Intervention for Women With Breast Cancer Completed NCT01354041 Phase 1
7 Feasibility and Efficacy of Internet-delivered CBT for Insomnia in a National Cohort of Danish Breast Cancer Survivors Unknown status NCT02444026 Not Applicable
8 Smart-phone Health Coaching Intervention to Promote Maintenance of Exercise in Breast Cancer Survivors:Protocol Unknown status NCT02620735 Not Applicable
9 A Therapy Intervention to Address Fear of Recurrence in Men and Women With Cancer Completed NCT02382315 Not Applicable
10 Targeted eHealth Intervention to Reduce Fear of Recurrence Among Breast Cancer Survivors Completed NCT03384992 Not Applicable
11 Fear of Cancer Recurrence (FoR) Trajectory During Radiation Treatment Completed NCT02599506
12 Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors Completed NCT02611544 Not Applicable
13 Evidence-informed Choice for Women Participating in Mammography Screening Completed NCT01335906 Not Applicable
14 (Cost-)Effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) in Cancer Patients Completed NCT02138513 Not Applicable
15 Needs Assessment After Cancer in Patients Treated for Breast Cancer Completed NCT03902964
16 Stress Management for Cancer Survivors Completed NCT01888523 Not Applicable
17 Health Benefits of Expressive Writing: Study One Completed NCT03546673 Not Applicable
18 Evaluation Study of Fear of Cancer Recurrence: Detection, Measure and Risk Factors in Lymphoma Survivorship Recruiting NCT03260855 Not Applicable
19 Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study Recruiting NCT03270995 Not Applicable
20 A Communication Skills Package to Prevent Fear of Cancer Recurrence Recruiting NCT03468881
21 Mind Body Program for Fear of Recurrence Recruiting NCT03695406 Not Applicable
22 Attention and Interpretation Modification (AIM) for Fear of Breast Cancer Recurrence: An Intervention Development Study Recruiting NCT01517945
23 Improving Emotion Regulation at the End of Breast Cancer Treatment Recruiting NCT03336827 Not Applicable
24 Yoga for Psychological Distress in Gynecologic, Gastrointestinal, or Thoracic Cancer Recruiting NCT03385577 Not Applicable
25 Conquer Fear SUPPORT Intervention in Supporting Patients With Stage III-IV Lung or Gynecologic Cancer Recruiting NCT03776253 Not Applicable
26 Cancer Related Cognitive Impairment After Chemotherapy: Evaluation of Potential Therapeutic Interventions Recruiting NCT03736460 Not Applicable
27 Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy Recruiting NCT03880617
28 Exercise During Active Surveillance for Prostate Cancer Recruiting NCT03203460 Not Applicable
29 MBCT for Cancer Patients in Follow-Up Recruiting NCT03591237 Not Applicable
30 Individual Follow-up After Rectal Cancer - Focus on the Needs of the Patient Recruiting NCT03622437 Not Applicable
31 Online MBSR Program for Cancer Survivors With Chronic Neuropathic Pain Recruiting NCT02758197 Not Applicable
32 Cognitively-Based Compassion Training for Breast Cancer Survivors Recruiting NCT03305952 Not Applicable
33 Acceptance and Commitment Therapy (ACT) for Anxious Cancer Survivors Recruiting NCT02550925 Not Applicable
34 Impact of an Intervention Combining Self-care and Hypnosis on the Well-being of Cancer Patients and Their Partners Recruiting NCT03144154 Not Applicable
35 Cognition in Allogeneic Stem Cell Transplanted Patients and Sports Recruiting NCT02533947 Not Applicable
36 EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer Recruiting NCT02889874 Not Applicable
37 Stepped-Care Telehealth for Distress in Rural Cancer Survivors Recruiting NCT03060096 Not Applicable
38 Follow-up of Endometrial Cancer Patients Active, not recruiting NCT01853865 Not Applicable
39 Survivorship in Lynch Syndrome Families Active, not recruiting NCT01126840
40 The SEAMLESS Study: Smartphone App-based Mindfulness for Cancer Survivors Enrolling by invitation NCT03557762 Not Applicable
41 A Research Study of Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma. Enrolling by invitation NCT03581188 Not Applicable
42 Mini-AFTERc Intervention for Fear of Cancer Recurrence Not yet recruiting NCT03763825 Not Applicable
43 An Individualised and Patient-centred Follow-up Program for Women With Gynaecological Cancer Not yet recruiting NCT03838861 Not Applicable
44 Investigating Fear Of Recurrence as a Modifiable Mechanism of Behavior Change Not yet recruiting NCT03853213 Not Applicable
45 Compare the Effects of NLSCP and Interactive ICT Supported HAP on Differentiate Diagnosed Thyroid Cancer Patients Not yet recruiting NCT03757637 Not Applicable
46 Effect of a Resilience Model-Based Care Plan in Newly Diagnosed Colorectal Cancer Patients Not yet recruiting NCT03277235 Not Applicable
47 Group Metacognitive Therapy for Anxiety and Depression in Cancer Survivors Not yet recruiting NCT03424512 Not Applicable
48 Delayed-immediate Versus Delayed Breast Reconstruction in Breast Cancer Patients With Mastectomy and Radiation Therapy Not yet recruiting NCT03730922 Not Applicable
49 Prospective Study Evaluating the Use of PROSPECT to Reduce Insomnia in Patients With Early Stage Breast Cancer Terminated NCT02712437 Not Applicable

Search NIH Clinical Center for Cancerophobia

Genetic Tests for Cancerophobia

Anatomical Context for Cancerophobia

MalaCards organs/tissues related to Cancerophobia:

42
Breast, Lung, Bone, Endothelial, Prostate, Thyroid

Publications for Cancerophobia

Articles related to Cancerophobia:

# Title Authors Year
1
When cancerophobia and denial lead to death. ( 19538809 )
2009
2
Cancerophobia and breast fixation. ( 204570 )
1978
3
MANAGEMENT OF THE PATIENT WITH CANCEROPHOBIA AND CANCER. ( 14149368 )
1964
4
Cancerophobia and delusion. ( 13672768 )
1959

Variations for Cancerophobia

Expression for Cancerophobia

Search GEO for disease gene expression data for Cancerophobia.

Pathways for Cancerophobia

GO Terms for Cancerophobia

Cellular components related to Cancerophobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral element GO:0000800 8.62 BRCA1 BRCA2

Biological processes related to Cancerophobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.63 BRCA1 MCIDAS PGR
2 cell cycle GO:0007049 9.54 BRCA1 BRCA2 MCIDAS
3 DNA recombination GO:0006310 9.43 BRCA1 BRCA2
4 double-strand break repair via homologous recombination GO:0000724 9.4 BRCA1 BRCA2
5 double-strand break repair GO:0006302 9.32 BRCA1 BRCA2
6 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.26 BRCA1 BRCA2
7 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.96 BRCA1 BRCA2
8 mammary gland development GO:0030879 8.85 PGR
9 chordate embryonic development GO:0043009 8.62 BRCA1 BRCA2

Molecular functions related to Cancerophobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 8.92 BRCA1 BRCA2 MCIDAS PGR

Sources for Cancerophobia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....